Valuation: Amplia Therapeutics Limited

Market Cap 71.86M 49.67M 43.57M 40.22M 37.17M 70.45M 4.76B 484M 188M 2.33B 187M 182M 8.08B P/E 2027 *
-6.09x
P/E 2028 * -23.3x
Enterprise Value 56.36M 38.96M 34.17M 31.55M 29.15M 55.26M 3.73B 379M 147M 1.83B 146M 143M 6.34B EV / Sales 2027 *
-
EV / Sales 2028 * 5.04x
Free-Float
84.81%
Yield 2027 *
-
Yield 2028 * -
1 day-3.57%
1 week-10.00%
Current month-6.90%
1 month+17.39%
3 months-20.59%
6 months-20.59%
Current year-10.00%
1 week 0.14
Extreme 0.135
0.16
1 month 0.1
Extreme 0.105
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.4
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 04/12/2022
Director of Finance/CFO - 30/09/2021
Chief Tech/Sci/R&D Officer - 11/05/2025
Director TitleAgeSince
Director/Board Member 70 01/09/2015
Chairman - 24/05/2018
Chairman - 29/06/2026
Date Insider Type Main position Quantity % Market Cap.
07/09/25Buy

Chairman

152,174 0.0392%
07/09/25Buy

Chairman

336,826 0.0868%
07/09/25Fiscal year

Founder

535,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-10.00%-61.43%+64.63% 53.4M
-1.53%-1.43%+71.67%+129.70% 57.72B
-2.45%-7.32%+65.23%+83.15% 52.65B
+3.27%+9.29%+20.20%+486.76% 24.46B
-0.81%+0.52%-15.01%-12.47% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.24%+5.40%+44.65%-26.41% 17.8B
+2.34%+14.18%+220.96%+380.99% 17.29B
-6.73%+9.90%+36.04% - 15.28B
-1.70%+3.12%+27.06%+190.57% 14.35B
Average -1.45%+5.24%+45.17%+143.47% 24.27B
Weighted average by Cap. -1.26%+2.96%+57.98%+141.64%

Financials

2027 *2028 *
Net sales - 10M 6.91M 6.06M 5.6M 5.17M 9.8M 662M 67.29M 26.15M 324M 25.96M 25.39M 1.12B
Net income -11.6M -8.02M -7.03M -6.49M -6M -11.37M -768M -78.05M -30.33M -376M -30.11M -29.45M -1.3B -3.6M -2.49M -2.18M -2.02M -1.86M -3.53M -238M -24.22M -9.41M -117M -9.34M -9.14M -405M
Net Debt -15.5M -10.71M -9.4M -8.68M -8.02M -15.2M -1.03B -104M -40.52M -502M -40.23M -39.35M -1.74B -21.5M -14.86M -13.03M -12.03M -11.12M -21.08M -1.42B -145M -56.21M -696M -55.81M -54.59M -2.42B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
09/07/26 A$0.1350 -3.57% 99,809
08/07/26 A$0.1400 -6.67% 1,263,334
07/07/26 A$0.1500 -3.23% 547,528
06/07/26 A$0.1550 +3.33% 904,101
03/07/26 A$0.1500 0.00% 647,557
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1400AUD
Average target price
0.4200AUD
Spread / Average Target
+200.00%

Annual profits - Rate of surprise